Market Overview

Global Blood Therapeutics Reaches Agreement With FDA On Sickle Cell Disease Treatment

Share:
Global Blood Therapeutics Reaches Agreement With FDA On Sickle Cell Disease Treatment
Related GBT
30 Stocks Moving In Friday's Mid-Day Session
25 Stocks Moving In Friday's Pre-Market Session
ROTY Edition 1 Volume 63: Argenx' Successful Offering, Amicus Submits NDA And Other Updates (Seeking Alpha)

Shares of Global Blood Therapeutics Inc (NASDAQ: GBT) spiked higher after-hours following a pair of news items announced in a company press release.

The company has reached an agreement with the FDA regarding the design of its pivotal trial for GBT440 in adults and adolescents with sickle cell disease. The Phase 3 study will begin screening patients by December with top-line data anticipated in the first half of 2019.

Dubbed The HOPE Study, the randomized, double-blind trail will enroll 400 patients age 12 and older.

Related Link: Global Blood Therapeutics Shares Spiking On Analyst's Positive Outlook

In other news, the company announced in an SEC filing that the company's Chief Medical Officer, Eleanor Ramos, will retire, effective today.

Global Blood Therapeutics shares were trading 13.8 percent higher at $20.20 after Monday's session.

Posted-In: Biotech News FDA After-Hours Center Movers General Best of Benzinga

 

Related Articles (GBT)

View Comments and Join the Discussion!